Dr. Alan Rothman of iCubed discusses two large grants, totaling $21.4 million dollars for The University of Rhode Island. He also comments on the current status of the government and the effects on academic groups obtaining grants. (interview starts at 1:15) Read the original PBN article on this topic. // _ // ]]>//

 https://convergenceri.com/ EpiVax commits resources to bring its Tregitope platform to clinic A pioneering firm in immunogenicity comes of age PHOTO BY SCOTT KINGSLEY Dr. Anne S. De Groot, CEO of EpiVax, Inc., is one of the original biotech pioneers in Rhode Island. Her firm’s slogan is “Science without Fear.” By Richard Asinof Posted 9/21/13 PROVIDENCE – At age 15, EpiVax is one of ...

Registration is now open and abstracts are being accpeted, for 7th Annual Vaccine Renaissance Conference Providence, RI Registration is now open for iCubed’s seventh annual Vaccine Renaissance Conference. The conference is slated for October 16-18, 2013 in Providence, Rhode Island. Abstracts are being accepted and the deadline is September 15th – send 250 word abstract to Patrick Lowney ...

PBN: URI dengue fever researcher wins $11M grant COURTESY WIKIMEDIA COMMONS MOSQUITOES CAN CARRY dengue fever, which URI Professor Alan Rothman will study with an $11.4 grant from the National Institutes of Health. By Patricia Daddona  PBN Staff Writer Posted 8/2/13 PROVIDENCE – A researcher of mosquito-borne illness at the University of Rhode Island has received an $11 million grant from ...

  A Brand New EpiVax Publication is Now Online! Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes (Tregitopes) Immune responses directed against viral capsid proteins constitute a main safety concern in the use of adeno-associated virus (AAV) as gene transfer vectors in humans. Pharmacological immunosuppression has been proposed as a solution ...

LIFE SCIENCES Vaccine development for H7N9 flu moving forward By Richard Asinof Contributing Writer Twitter: @RichardAsinof Posted 5/20/13 PROVIDENCE – It has been a very busy month and half for Dr. Anne S. De Groot and her team at EpiVax, a bioscience firm based in the Knowledge District, which celebrated its 15th birthday on May 17. De Groot, the chief science officer and ...

EpiVax Congratulates Dr. Leslie Cousens and Dr. Annie De Groot! Scientific Director of Protein Therapeutics and Lead Scientist on the Tregitope project at EpiVax, Dr. Leslie Cousens and EpiVax CEO/CSO Dr. Annie De Groot are two of five RI Bioscience Award winners for 2013! “The Tech Collective’s Rhode Island Bioscience Awards honor those who are innovating ...

Application of IgG-Derived Natural Treg Epitopes (IgG Tregitopes) to Antigen-Specific Tolerance Induction in a Murine Model of Type 1 Diabetes Abstract HLA class II-restricted regulatory T cell (Treg) epitopes in IgG (also called “Tregitopes”) have been reported to suppress immune responses to coadministered antigens by stimulating the expansion of natural Tregs (nTregs). Here we evaluate their impact ...

                                                          BIOATLA COMBINES EPIVAX’S IMMUNOGENICITY SCREENING INTO THEIR EXPRESS HUMANIZATIONTM PLATFORM  EpiVax BioAtla Collaboration Page Providence and San Diego, 24 April 2013 – EpiVax Inc., an unique immunology company with a strong focus ...

An Update on EpiVax’ H7N9 “FastVax” Progress EpiVax scientists are currently in discussions with groups in China, Canada and the US about producing a vaccine. Here we highlight a few key points about the current progress of EpiVax’ FastVax vaccine design: (1) While H7N9 influenza may be mutable, selecting highly conserved and immunogenic components for vaccines is our ...

Providence Business News Article: life sciences EpiVax, partners move ahead on H7N9 flu vaccine production COURTESY UNIVERSITY OF RHODE ISLAND EPIVAX, the life sciences company founded by Dr. Anne S. De Groot, is engaged in pioneering efforts with Aldevron, a life sciences production company, and the Army Medical Research Institute of Infectious Diseases to produce vaccine to combat ...

H7N9 (Shanghai 2013) Immunogenicity Analysis

EpiVax creates recipe for novel vaccine approach to new flu strain COURTESY UNIVERSITY OF RHODE ISLAND DR. ANNE S. DE GROOT and her team at EpiVax have come up with a novel way to produce a vaccine to combat what she fears may be a serious flu outbreak linked to a new strain of the virus ...

Denver Post: Garrett: Is this how a pandemic would start? See how would EpiVax fight this type of threat.   Posted:   04/07/2013 12:01:00 AM MDT By Laurie Garrett Foreign Policydenverpost.com A worker rests while another pulls up a dead pig from the Huangpu River in Jiaxing, in eastern China. Some 15,000 dead animals have littered the river that runs through ...

Evaluation of H7N9 (Shanghai 2013) for T cell epitopes and cross-reactivity with circulating strains of Influenza (see slides below). Extremely Rapid H7N9 Vaccine Design by EpiVax EpiVax performed an extremely rapid analysis of the H7N9 vaccine sequence that is associated with an increasing number of deaths in Shanghai, China. One purpose was to show that we could design ...